MA34321B1 - Formulation à libération prolongée - Google Patents

Formulation à libération prolongée

Info

Publication number
MA34321B1
MA34321B1 MA35468A MA35468A MA34321B1 MA 34321 B1 MA34321 B1 MA 34321B1 MA 35468 A MA35468 A MA 35468A MA 35468 A MA35468 A MA 35468A MA 34321 B1 MA34321 B1 MA 34321B1
Authority
MA
Morocco
Prior art keywords
release formulation
salt
present
compound
extended release
Prior art date
Application number
MA35468A
Other languages
English (en)
Inventor
Tomomichi Futo
Hikaru Taira
Seitaro Mizukami
Naoyuki Murata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34321(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA34321B1 publication Critical patent/MA34321B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/005—Processes for mixing polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une formule à libération prolongée comprenant un dérivé de métastine et un polymère lactique de masse moléculaire moyenne en poids compris entre environ 5000 et environ 40 000, ou l'un de ses sels. La formule à libération prolongée selon la présente invention libère lentement et de façon stable le composé (I) ou l'un de ses sels sur une durée importante et applique les effets thérapeutiques du composé (I) ou de l'un de ses sels sur une durée importante. En outre, la formule à libération prolongée selon la présente invention, qui améliore le confort du patient en réduisant la fréquence d'administration, constitue un excellent médicament clinique.
MA35468A 2010-06-25 2011-06-23 Formulation à libération prolongée MA34321B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010144792 2010-06-25
PCT/JP2011/064992 WO2011162413A1 (fr) 2010-06-25 2011-06-23 Formule à libération prolongée

Publications (1)

Publication Number Publication Date
MA34321B1 true MA34321B1 (fr) 2013-06-01

Family

ID=44583663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35468A MA34321B1 (fr) 2010-06-25 2011-06-23 Formulation à libération prolongée

Country Status (25)

Country Link
US (2) US20130210742A1 (fr)
EP (1) EP2585091B1 (fr)
JP (1) JP5838173B2 (fr)
KR (1) KR20130097088A (fr)
CN (1) CN103025343B (fr)
AR (1) AR081980A1 (fr)
AU (1) AU2011270093A1 (fr)
BR (1) BR112012032544A2 (fr)
CA (1) CA2802209C (fr)
CL (1) CL2012003645A1 (fr)
CR (1) CR20120604A (fr)
DO (1) DOP2012000304A (fr)
EA (1) EA021663B1 (fr)
EC (1) ECSP12012350A (fr)
ES (1) ES2513569T3 (fr)
IL (1) IL223266A0 (fr)
MA (1) MA34321B1 (fr)
MX (1) MX2012014265A (fr)
PE (1) PE20130276A1 (fr)
PH (1) PH12012502548A1 (fr)
SG (1) SG186070A1 (fr)
TN (1) TN2012000562A1 (fr)
TW (1) TW201204378A (fr)
UY (1) UY33465A (fr)
WO (1) WO2011162413A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TWI778979B (zh) 2016-09-30 2022-10-01 瑞士商麥歐文科學有限公司 治療女性不孕症之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
CN1269870C (zh) * 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
WO2002085399A1 (fr) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
ZA200902452B (en) * 2006-10-25 2010-07-28 Takeda Pharmaceutical Metastin derivatives and use thereof
MX2009006653A (es) * 2006-12-18 2009-07-02 Takeda Pharmaceutical Composicion de liberacion prolongada y metodo para producirla.
EP2277900A4 (fr) * 2008-04-24 2011-08-03 Takeda Pharmaceutical Dérivé de métastine et son utilisation
JP2012513982A (ja) * 2008-12-29 2012-06-21 武田薬品工業株式会社 癌の予防・治療剤
CN102665690A (zh) * 2009-12-22 2012-09-12 武田药品工业株式会社 缓释制剂

Also Published As

Publication number Publication date
AU2011270093A1 (en) 2013-01-10
CN103025343B (zh) 2015-03-25
WO2011162413A1 (fr) 2011-12-29
EP2585091A1 (fr) 2013-05-01
IL223266A0 (en) 2013-02-03
EP2585091B1 (fr) 2014-09-10
CA2802209C (fr) 2019-12-31
ES2513569T3 (es) 2014-10-27
CA2802209A1 (fr) 2011-12-29
PE20130276A1 (es) 2013-03-20
JP5838173B2 (ja) 2016-01-06
UY33465A (es) 2012-01-31
BR112012032544A2 (pt) 2016-10-11
TN2012000562A1 (en) 2014-04-01
AR081980A1 (es) 2012-10-31
CL2012003645A1 (es) 2013-04-05
JP2013530926A (ja) 2013-08-01
ECSP12012350A (es) 2014-02-28
EA021663B1 (ru) 2015-08-31
SG186070A1 (en) 2013-01-30
MX2012014265A (es) 2013-01-18
US20130210742A1 (en) 2013-08-15
DOP2012000304A (es) 2013-01-31
PH12012502548A1 (en) 2013-02-11
TW201204378A (en) 2012-02-01
CR20120604A (es) 2013-03-21
KR20130097088A (ko) 2013-09-02
CN103025343A (zh) 2013-04-03
EA201291303A1 (ru) 2013-04-30
US20180243422A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
Geng et al. Biomimetic nanovehicle-enabled targeted depletion of intratumoral Fusobacterium nucleatum synergizes with PD-L1 blockade against breast cancer
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
Lind et al. Nicotinamide for skin-cancer chemoprevention
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
NZ701915A (en) High-concentration monoclonal antibody formulations
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
EP3147285A3 (fr) Composés de purinone en tant qu'inhibiteurs de kinase
WO2007149310A3 (fr) Nano-composants multiphasiques biofonctionnels et procédés d'utilisation desdits nano-composants
WO2010085100A2 (fr) Nouveau domaine transmembranaire cellulaire et système de transduction intracellulaire contenant ce domaine
EP1450775B1 (fr) Inhibiteurs de c-kit pour traiter des infections bacteriennes
Rosborough et al. Adenosine triphosphate‐competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection
US10517924B2 (en) High density lipoprotein nanoparticles for inflammation
Kumarasingam et al. Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола
MA34321B1 (fr) Formulation à libération prolongée
Sukhithasri et al. Mycobacterium tuberculosis treatment modalities and recent insights
MA33910B1 (fr) Formulation à libération prolongée
Ellis et al. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever
Subbiah et al. Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma
Soria et al. Acute dermal abscesses caused by Serratia marcescens
West et al. Solitary supratentorial Listeria monocytogenes brain abscess in an immunocompromised patient
Tang et al. Tigecycline therapy for bacteremia and aortitis caused by Salmonella enterica serotype Choleraesuis: a case report
Serna et al. Finding of leishmanicidal activity of 14-hydroxylunularin in mice experimentally infected with Leishmania infantum
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions